onkoserv

Indikation: Hodgkin-Lymphom

zurück

2012

Comparing long-term toxicity and efficacy of combined modality treatment including extended- or involved-field radiotherapy in early-stage Hodgkin's lymphoma

Ann Oncol 23 (2012) 2953-2959

Long-term outcomes after high dose therapy and autologous haematopoietic cell rescue for refractory/relapsed Hodgkin lymphoma

Br J Haematol 159 (2012) 329-339

Response-dependent and reduced treatment in lower risk Hodgkin lymphoma in children and adolescents, results of P9426: A report from the Children's Oncology Group

Ped Blood Cancer 59 (2012) 1259-1265

Impact of low-dose involved-field radiation therapy on pediatric patients with lymphocyte-predominant Hodgkin lymphoma treated with chemotherapy: A report from the Children's Oncology Group

Ped Blood Cancer 59 (2012) 1284-1289

Panobinostat in Patients With Relapsed/Refractory Hodgkin's Lymphoma After Autologous Stem-Cell Transplantation: Results of a Phase II Study

J Clin Oncol 30 (2012) 2197-2203

Brentuximab vedotin for relapsed or refractory CD30+ hematologic malignancies: the German Hodgkin Study Group experience

Blood 120 (2012) 1470-1472 (=Link zum HTML-Volltext

Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation

Blood 20 (2012) 560-568

Association Between Radiotherapy vs No Radiotherapy Based on Early Response to VAMP Chemotherapy and Survival Among Children With Favorable-Risk Hodgkin Lymphoma

JAMA 307 (2012) 2609-2616

Treatment outcome after low intensity chemotherapy [CVP] in children and adolescents with early stage nodular lymphocyte predominant Hodgkin’s lymphoma – An Anglo-French collaborative repor

Eur J Cancer 48 (2012) 1700-1706

Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma

J Clin Oncol 30 (2012) 2183-2189

A randomized trial of brief treatment of early- stage Hodgkin lymphoma: Is it effective?

Hematol Oncol Stem Cell Ther 5 (2012) 36-41

Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma

Blood 119 (2012) 4123-4128

Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial

Lancet 379 (2012) Online first 4. 4. 2012

Dose-Adjusted EPOCH-Rituximab Combined With Fludarabine Provides an Effective Bridge to Reduced-Intensity Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Lymphoid Malignancies

J Clin Oncol 30 (2012) 830-836

ABVD Alone versus Radiation-Based Therapy in Limited-Stage Hodgkin's Lymphoma

N Engl J Med 366 (2012) 399-408

Dose-Intensification in Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD14 Trial

J Clin Oncol 30 (2012) 907-913
2011

Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial

Lancet Oncol 12 (2011) 1222-1228

Reduced incidence of second solid tumors in survivors of childhood Hodgkin's lymphoma treated without radiation therapy

Ann Oncol 22 (2011) 2569-2574

Eight Cycles of Escalated-Dose BEACOPP Compared With Four Cycles of Escalated-Dose BEACOPP Followed by Four Cycles of Baseline-Dose BEACOPP With or Without Radiotherapy in Patients With Advanced-Stage Hodgkin's Lymphoma: Final Analysis of the HD12 Trial of the German Hodgkin Study Group

J Clin Oncol 29 (2011) 4234-4242

Long-Term Follow-Up Analysis of HD9601 Trial Comparing ABVD Versus Stanford V Versus MOPP/EBV/CAD in Patients With Newly Diagnosed Advanced-Stage Hodgkin's Lymphoma: A Study From the Intergruppo Italiano Linfomi

J Clin Oncol 29 (2011) 4227-4233